Overview

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Status:
Active, not recruiting

Trial end date:
2022-02-17

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Capecitabine